Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

HERZLIYA, Israel, March 27, 2019 – Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses,…

Continue ReadingOrasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia